A Glimpse Into The Expert Outlook On Pfizer Through 9 Analysts
Portfolio Pulse from Benzinga Insights
Nine analysts have provided varied opinions on Pfizer (NYSE:PFE) over the past quarter, with the majority being somewhat bullish. The average 12-month price target is $42.22, reflecting a 3.33% increase from the previous average. Key analysts have maintained or raised their ratings and price targets, indicating a positive outlook despite recent revenue challenges.
July 01, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a somewhat bullish outlook on Pfizer with an average 12-month price target of $42.22, reflecting a 3.33% increase. Key analysts have maintained or raised their ratings and price targets, indicating a positive sentiment despite recent revenue challenges.
The majority of analysts are somewhat bullish on Pfizer, with an average price target increase of 3.33%. Key analysts have maintained or raised their ratings, indicating a positive sentiment. Despite a recent revenue decline, Pfizer's strong net margin, ROE, and ROA, along with prudent debt management, support a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100